Original article

Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases

Expand
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-11-30

  Online published: 2022-03-17

Abstract

Objective To analyze the clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm (IOPN). Methods Five cases with pancreatic IOPN were in Ruijin Hospital including 3 female and 2 male, and the average age (60.0±10.4) years old. The clinical features combined with gross and microscopic pathology, immunophenotype and prognosis were analyzed. Results Two cases had abdominal pain including 1 case losing 5 kg during the period of 6 months. Three patients were found on physical examination. Pancreatic tumor in 2 cases located at the head, in 3 cases at the head and the body, the neck, and the body, respectively. The test showed serological CA724 elevated in 1 case, and other serological indexes were normal. The gross pathology showed that the tumor was multilocular cystic, cystic solid or solid. The solid area was gray-white, fragile, and the inner wall of the cyst was smooth or with papillary protrusions. The microscopic pathology showed that the tumor was ductal growth with complex branched papillary structure in the capsule. The tumor cells lining the papilla had eosinophilic granules, and the cell was atypia and contained typical nucleolus. Goblet cells could be seen among tumor cells. Mucus secretion was present and without significance. Immunohistochemistry showed cytokeratin 7 positive (3/4), MUC1 and MUC6 positive (4/4), MUC5AC positive (3/3), hepatocyte antigen (Hep Par 1) positive (3/4). CK20 or MUC2 in individual tumor cells were positive and SYN and CgA negative (2/2). There were 4 cased with following-up without recurrence or metastasis in any case. Conclusions IOPN is a rare pancreatic epithelial tumor with low malignancy, which is divided from pancreatic intraductal papillary mucinous neoplasms, and has unique clinical and pathological characteristics. Further study with recognition is needed for rare disease of IOPN.

Cite this article

YANG Chunxue, XU Haimin, DA Qian . Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases[J]. Journal of Surgery Concepts & Practice, 2022 , 27(01) : 52 -57 . DOI: 10.16139/j.1007-9610.2022.01.013

References

[1] Adsay NV, Adair CF, Heffess CS, et al. Intraductal oncocytic papillary neoplasms of the pancreas[J]. Am J Surg Pathol, 1996, 20(8):980-994.
[2] Basturk O, Tan M, Bhanot U, et al. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes[J]. Mod Pathol, 2016, 29(9):1058-1069.
[3] D′Onofrio M, de Robertis R, Tinazzi Martini P, et al. Oncocytic intraductal papillary mucinous neoplasms of the pancreas: imaging and histopathological findings[J]. Pancreas, 2016, 45(9):1233-1242.
[4] Wang T, Askan G, Adsay V, et al. Intraductal oncocytic papillary neoplasms: clinical-pathologic characterization of 24 cases, with an emphasis on associated invasive carcinomas[J]. Am J Surg Pathol, 2019, 43(5):656-661.
[5] Kallen ME, Naini BV. Intraductal oncocytic papillary neoplasms of the pancreas[J]. Arch Pathol Lab Med, 2016, 140(9):992-996.
[6] Liszka L, Pajak J, Zielińska-Pajak E, et al. Intraductal oncocytic papillary neoplasms of the pancreas and bile ducts: a description of five new cases and review based on a systematic survey of the literature[J]. J Hepatobiliary Pancreat Sci, 2010, 17(3):246-261.
[7] Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas[J]. Gut, 2011, 60(4):509-516.
[8] Klöppel G, Basturk O, Schlitter AM, et al. Intraductal neoplasms of the pancreas[J]. Semin Diagn Pathol, 2014, 31(6):452-466.
[9] Patel SA, Adams R, Goldstein M, et al. Genetic analysis of invasive carcinoma arising in intraductal oncocytic papillary neoplasm of the pancreas[J]. Am J Surg Pathol, 2002, 26(8):1071-1077.
[10] Adsay NV, Longnecker DS, Klimstra DS. Pancreatic tumors with cystic dilatation of the ducts: intraductal pa-pillary mucinous neoplasms and intraductal oncocytic papillary neoplasms[J]. Semin Diagn Pathol, 2000, 17(1):16-30.
[11] Kang MJ, Lee KB, Jang JY, et al. Evaluation of clinical meaning of histological subtypes of intraductal papillary mucinous neoplasm of the pancreas[J]. Pancreas, 2013, 42(6):959-966.
[12] Grützmann R, Niedergethmann M, Pilarsky C, et al. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment[J]. Oncologist, 2010, 15(12):1294-1309.
[13] Terris B, Dubois S, Buisine MP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions[J]. J Pathol, 2002, 197(5):632-637.
[14] Basturk O, Chung SM, Hruban RH, et al. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas[J]. Virchows Arch, 2016, 469(5):523-532.
[15] Welter C, Kovacs G, Seitz G, et al. Alteration of mitochondrial DNA in human oncocytomas[J]. Genes Chromosomes Cancer, 1989, 1(1):79-82.
[16] Mattiolo P, Hong SM, Paolino G, et al. CD117 is a specific marker of intraductal papillary mucinous neoplasms (IPMN) of the pancreas, oncocytic subtype[J]. Int J Mol Sci, 2020, 21(16):5794.
[17] Schönleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma(IPMN/IPMC) of the pancreas[J]. Cancer Lett, 2007, 249(2):242-248.
[18] Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraduc-tal papillary mucinous neoplasms of the pancreas[J]. Sci Rep, 2011, 1:161.
[19] Amato E, Molin MD, Mafficini A, et al. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas[J]. J Pathol, 2014, 233(3):217-227.
[20] Kuboki Y, Shimizu K, Hatori T, et al. Molecular biomar-kers for progression of intraductal papillary mucinous neo-plasm of the pancreas[J]. Pancreas, 2015, 44(2):227-235.
[21] Singhi AD, Wood LD, Parks E, et al. Recurrent rearrangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct[J]. Gastroenterology, 2020, 158(3):573-582.e572.
[22] Muraki T, Uehara T, Sano K, et al. A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm?[J]. Pathol Res Pract, 2015, 211(12):1034-1039.
Outlines

/